These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25217649)

  • 1. Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease.
    Imazu M; Takahama H; Asanuma H; Funada A; Sugano Y; Ohara T; Hasegawa T; Asakura M; Kanzaki H; Anzai T; Kitakaze M
    Am J Physiol Heart Circ Physiol; 2014 Nov; 307(10):H1504-11. PubMed ID: 25217649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study.
    Smith DH; Thorp ML; Gurwitz JH; McManus DD; Goldberg RJ; Allen LA; Hsu G; Sung SH; Magid DJ; Go AS
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):333-42. PubMed ID: 23685625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast Growth Factor-23 and Carotid Artery Intima Media Thickness in Chronic Kidney Disease.
    Yilmaz G; Ustundag S; Temizoz O; Sut N; Demir M; Ermis V; Sevinc C; Ustundag A
    Clin Lab; 2015; 61(8):1061-70. PubMed ID: 26427152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA.
    Almahmoud MF; Soliman EZ; Bertoni AG; Kestenbaum B; Katz R; Lima JAC; Ouyang P; Miller PE; Michos ED; Herrington DM
    J Am Heart Assoc; 2018 Sep; 7(18):e008334. PubMed ID: 30371180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure.
    Flores-Blanco PJ; Manzano-Fernández S; Pérez-Calvo JI; Pastor-Pérez FJ; Ruiz-Ruiz FJ; Carrasco-Sánchez FJ; Morales-Rull JL; Pascual-Figal D; Galisteo-Almeda L; Januzzi JL
    Clin Cardiol; 2015 Feb; 38(2):106-13. PubMed ID: 25663560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure.
    Bosselmann H; Tonder N; Sölétormos G; Gaborit F; Rossing K; Iversen K; Goetze JP; Gustafsson F; Schou M
    ESC Heart Fail; 2017 Nov; 4(4):554-562. PubMed ID: 29154425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes.
    O'Meara E; Rouleau JL; White M; Roy K; Blondeau L; Ducharme A; Neagoe PE; Sirois MG; Lavoie J; Racine N; Liszkowski M; Madore F; Tardif JC; de Denus S;
    Circ Heart Fail; 2014 Sep; 7(5):773-81. PubMed ID: 25027873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kansas City Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed Heart Failure: Chronic Renal Insufficiency Cohort Study.
    Mishra RK; Yang W; Roy J; Anderson AH; Bansal N; Chen J; DeFilippi C; Delafontaine P; Feldman HI; Kallem R; Kusek JW; Lora CM; Rosas SE; Go AS; Shlipak MG;
    Circ Heart Fail; 2015 Jul; 8(4):702-8. PubMed ID: 25985796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
    De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
    Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of glomerular filtration rate estimation equations in acute heart failure with preserved versus reduced ejection fraction.
    Casado Cerrada J; Carrasco Sánchez FJ; Pérez-Calvo JI; Manzano L; Formiga F; Aramburu Bodas O; Conde A; Quirós R; Pérez Bocanegra C; Montero-Pérez-Barquero M;
    Int J Clin Pract; 2015 Aug; 69(8):829-39. PubMed ID: 25651522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure.
    Wohlfahrt P; Melenovsky V; Kotrc M; Benes J; Jabor A; Franekova J; Lemaire S; Kautzner J; Jarolim P
    JACC Heart Fail; 2015 Oct; 3(10):829-39. PubMed ID: 26450001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.
    Tanaka S; Fujita S; Kizawa S; Morita H; Ishizaka N
    PLoS One; 2016; 11(7):e0156860. PubMed ID: 27400031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease.
    Santer L; López B; Ravassa S; Baer C; Riedel I; Chatterjee S; Moreno MU; González A; Querejeta R; Pinet F; Thum T; Díez J
    Hypertension; 2019 Apr; 73(4):820-828. PubMed ID: 30686085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease.
    Canney M; Djurdjev O; Tang M; Zierold C; Blocki F; Wolf M; Levin A
    Am J Nephrol; 2019; 50(2):105-114. PubMed ID: 31238301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical markers of cardiovascular disease predict adverse outcomes in chronic kidney disease patients with normal left ventricular ejection fraction.
    Sulemane S; Panoulas VF; Bratsas A; Grapsa J; Brown EA; Nihoyannopoulos P
    Int J Cardiovasc Imaging; 2017 May; 33(5):687-698. PubMed ID: 28120157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.